|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
FAM175B is a reported regulator of p53 and suppresses tumorigenesis in numerous types of cancer, but very little is known about its function in esophageal squamous cell carcinomas (ESCCs), almost 70% of which exhibit mutations in p53.
|
30854784 |
2019 |
|
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, we report that ABRO1 deficiency results in a remarkable attenuation in the syndrome severity of NLRP3-associated inflammatory diseases, including MSU- and Alum-induced peritonitis and LPS-induced sepsis in mice.
|
30787184 |
2019 |
|
Sepsis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, we report that ABRO1 deficiency results in a remarkable attenuation in the syndrome severity of NLRP3-associated inflammatory diseases, including MSU- and Alum-induced peritonitis and LPS-induced sepsis in mice.
|
30787184 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
FAM175B promotes apoptosis by inhibiting ATF4 ubiquitination in esophageal squamous cell carcinoma.
|
30854784 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
FAM175B is a reported regulator of p53 and suppresses tumorigenesis in numerous types of cancer, but very little is known about its function in esophageal squamous cell carcinomas (ESCCs), almost 70% of which exhibit mutations in p53.
|
30854784 |
2019 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
FAM175B is a reported regulator of p53 and suppresses tumorigenesis in numerous types of cancer, but very little is known about its function in esophageal squamous cell carcinomas (ESCCs), almost 70% of which exhibit mutations in p53.
|
30854784 |
2019 |
|
High Grade Intraepithelial Neoplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we report that FAM175B expression is downregulated in high-grade intraepithelial neoplasia (t = 2.44, P = 0.031) and ESCC (t = 5.664, P < 0.001) tissues relative to that in adjacent normal esophageal tissues.
|
30854784 |
2019 |
|
Trichohepatoenteric Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, we report that ABRO1 deficiency results in a remarkable attenuation in the syndrome severity of NLRP3-associated inflammatory diseases, including MSU- and Alum-induced peritonitis and LPS-induced sepsis in mice.
|
30787184 |
2019 |
|
Extrapulmonary Small Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
FAM175B expression loss may be an early diagnostic biomarker in ESCC patients.
|
30854784 |
2019 |
|
Coronary Arteriosclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Abro1 was predominantly expressed in the heart and its protein level was regulated following experimentally induced myocardial ischemia/reperfusion (MI/R) injury.
|
21195082 |
2011 |
|
Coronary heart disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our results demonstrate that Abro1 protein level substantially increases in myocardial injury and coronary artery disease and this up-regulation is part of a novel cardioprotective mechanism.
|
21195082 |
2011 |
|
Myocardial Infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Reducing the Abro1 protein level exacerbated cellular damage and cell death of cardiomyocytes due to MI/R injury.
|
21195082 |
2011 |
|
Myocardial Ischemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Abro1 was predominantly expressed in the heart and its protein level was regulated following experimentally induced myocardial ischemia/reperfusion (MI/R) injury.
|
21195082 |
2011 |
|
Coronary Artery Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, in patients with coronary artery disease (CAD), there was a dramatic increase in Abro1 protein level in the myocardial infarction (MI) area.
|
21195082 |
2011 |